|
|
Article: Replidyne Raises $40M, Adds To Pipeline With Antibacterial Drug.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Replidyne Inc. closed its largest financing, a $40 million second round, and concurrently in-licensed a late-stage compound to treat bacterial infections.
Replidyne obtained exclusive rights to faropenem daloxate from Tokyo-based Daiichi Suntory Pharma in the U.S. and Canada, retaining an exclusive option for rights everywhere but Japan. It will become the company's lead product and could reach the market sometime after 2006, when the filing of a new drug application is expected.
Financial terms of the in-licensing deal were not disclosed, but it includes a standard up-front payment and potential milestone and royalty payments down ...